Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
Pooled result · Fat body massResult — go to the resultWMD −2.25 kg 95% CI −3.40 to −1.10Authors' conclusion
Compared with the controls, GLP-1 receptor-based agonist users experienced greater reductions in fat body mass, with body shaping effects in terms of both subcutaneous fat mass and visceral fat mass. Although greater reductions in lean body mass were also observed in GLP-1 receptor-based agonist users, the changes in lean mass percentage were comparable between the users and non-users.
Study context
- Population
- RCTs of GLP-1 RA or GIP/GLP-1 receptor dual agonist reporting changes in body composition; databases searched from inception to October 202319 RCTs
- Comparison
- GLP-1 receptor-based agonist vs controls
- Outcome
- Fat body mass
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
As reported in the abstract
WMD
−2.25 kg
95% CI −3.40 to −1.10
GLP-1 receptor-based agonistvs Controls
WMD −2.25 kg (95% CI −3.40 to −1.10)
Further pooled results
| Outcome | WMD (cm²) (95% CI) | |
|---|---|---|
| Subcutaneous fat area | −38.35 (−54.75 to −21.95) | |
| Visceral fat area | −14.61 (−23.77 to −5.44) | |
| −100−50050Difference, cm² (linear scale) |
| Outcome | WMD (kg) (95% CI) | |
|---|---|---|
| Lean body massGreater reduction with GLP-1 receptor-based agonist | −1.02 (−1.46 to −0.57) | |
| −2−101Difference, kg (linear scale) |
Lean mass percentage
- Changes in lean mass percentage comparable between users and non-users
Original publication
Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis. Diabetes Obes Metab. Published 21 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →